Back
75· Active
Health & Science1h 24m ago
An independent FDA advisory panel voted unanimously that the benefits of the Alzheimer’s drug donanemab outweigh its risks for patients in early stages of the disease.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) & Eli Lilly
What
An independent FDA advisory panel voted unanimously that the benefits of the Alzheimer’s drug donanemab outweigh its risks for patients in early stages of the disease.
When
Wed, 10 Jun 2026 13:40:05 GMT · 1h 24m ago
Where
Silver Spring, Maryland, USA · 39.0331°N, 76.9904°W
Why
Clinical trial data demonstrated that the treatment significantly slows cognitive and functional decline by clearing amyloid plaques from the brain.
The Frontline Impact
How this affects you
Prospective patients and families may soon have access to a new treatment option that targets the underlying pathology of Alzheimer's, potentially extending independence for those in early stages.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.